J P Morgan Chase & Co set a €85.00 ($101.19) price target on Sanofi SA (EPA:SAN) in a research note published on Thursday morning. The firm currently has a neutral rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Jefferies Group LLC set a €92.00 ($109.52) target price on shares of Sanofi SA and gave the company a neutral rating in a research report on Monday, May 29th. Credit Suisse Group set a €95.00 ($113.10) target price on shares of Sanofi SA and gave the company a buy rating in a research report on Tuesday, July 4th. Kepler Capital Markets set a €89.00 ($105.95) target price on shares of Sanofi SA and gave the company a buy rating in a research report on Wednesday, July 26th. Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) target price on shares of Sanofi SA and gave the company a neutral rating in a research report on Wednesday, May 24th. Finally, Berenberg Bank set a €97.00 ($115.48) target price on shares of Sanofi SA and gave the company a neutral rating in a research report on Saturday, May 20th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of €87.88 ($104.61).

Shares of Sanofi SA (SAN) traded down 0.84% during trading on Thursday, hitting €81.37. 5,934,268 shares of the stock were exchanged. The company has a market cap of €102.18 billion and a P/E ratio of 11.35. Sanofi SA has a 1-year low of €24.55 and a 1-year high of €82.67. The firm’s 50-day moving average is €26.11 and its 200 day moving average is €25.99.

WARNING: This report was reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/15/sanofi-sa-san-given-a-85-00-price-target-at-j-p-morgan-chase-co.html.

Sanofi SA Company Profile

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.